초록접수 현황
| 17F-260 | 구연 미채택시 포럼 발표 |
Surgical Rebiopsy in Advanced Non-small Cell Lung Cancer Resistant to Previous Chemotherapy
Sumin Shin, Jong Ho Cho, Hong Kwan Kim, Yong Soo Choi, Jhingook Kim, Jae Ill Zo, Young Mog Shim
Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
Purpose : To optimize the personalized medicine for advanced NSCLC sufficient tumor tissue is mandatory to analyze molecular and genetic profile. The demand for repeateed biopsy is increasing, it is more difficult to obtain specimen after initial treatment. The aim of this study was to evaluate the impact of surgical rebiopsy in advanced NSCLC.
Methods : From Jan 2014 to Mar 2017, 146 consecutive patients underwent surgical rebiopsy for NSCLC which was resistant to prior chemotherapy. Their medical record were reviewed retrospectively.
Results : There were 60 male and 86 female patients with mean age of 57 years. Adenocarcinoma was most common histologic type(n=142,93%).Among them, 107 patients represent EGFR mutation, deletion in exon 19(n=73) was most frequently observed. The mean number of chemotherapy alteration was 2(range1-6) The median time between initial treatment and rebiopsy was 17.4 months(IQR9-25).
One hundred and seven patients(73%) underwent pleura biopsy, 22 underwent lung resection and 12 patients underwent both pleural and lung resection. Most procedure underwent video-assisted thoracic surgery(n=136,93%), 10patients required mini-thoracotomy. Median postoperative hospital stay was 4 days(IQR,3-6) and the 30-day mortality was 2.7%.
All specimens were confirmed as NSCLC and adequate for mutational and genetic analysis except 2 patients. After surgery, 129 patients can resume chemotherapy. Of those, 85 patients were enrolled clinical trial or treated with new target agent. Thirty nine patients were treated with cytotoxic chemotherapy and 5 patients continued with prior target agent.
Conclusion : Surgical rebiopsy can detect changes in cancer characteristics and may be used in therapeutic decision making in advanced NSCLC resistant to previous treatment.
Methods : From Jan 2014 to Mar 2017, 146 consecutive patients underwent surgical rebiopsy for NSCLC which was resistant to prior chemotherapy. Their medical record were reviewed retrospectively.
Results : There were 60 male and 86 female patients with mean age of 57 years. Adenocarcinoma was most common histologic type(n=142,93%).Among them, 107 patients represent EGFR mutation, deletion in exon 19(n=73) was most frequently observed. The mean number of chemotherapy alteration was 2(range1-6) The median time between initial treatment and rebiopsy was 17.4 months(IQR9-25).
One hundred and seven patients(73%) underwent pleura biopsy, 22 underwent lung resection and 12 patients underwent both pleural and lung resection. Most procedure underwent video-assisted thoracic surgery(n=136,93%), 10patients required mini-thoracotomy. Median postoperative hospital stay was 4 days(IQR,3-6) and the 30-day mortality was 2.7%.
All specimens were confirmed as NSCLC and adequate for mutational and genetic analysis except 2 patients. After surgery, 129 patients can resume chemotherapy. Of those, 85 patients were enrolled clinical trial or treated with new target agent. Thirty nine patients were treated with cytotoxic chemotherapy and 5 patients continued with prior target agent.
Conclusion : Surgical rebiopsy can detect changes in cancer characteristics and may be used in therapeutic decision making in advanced NSCLC resistant to previous treatment.
책임저자: Sumin Shin
Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
발표자: Sumin Shin, E-mail : essennee@gmail.com